Laboratorios Farmacéuticos ROVI - 2021: A pinnacle year
Laboratorios Farmacéuticos ROVI (ROVI) has reported a strong set of FY20 results, with all pillars of the business contributing to revenue growth of 10% and EBITDA margin expansion of 650bp to 22.4%. Total revenues of €421.1m were driven by its LMWH franchise (+14%) and high-value, toll manufacturing business (+39%), which has been catapulted into the international spotlight. In July 2020, ROVI signed a deal with US biotech Moderna to provide finished COVID-19 vaccine mRNA-1273 for supply ex-US. ROVI’s revised FY21 guidance is for 20–30% revenue growth and we expect toll manufacturing to be a substantial contributor. DORIA remains on track in the US for potential approval and launch in 2022, while the EMA’s request for an additional PK study has delayed European approval and launch to 2022. We value ROVI at €2.34bn or €41.7/share.Laboratorios Farmaceuticos Rovi is engaged in the sale of its own pharmaceutical products and the distribution of other products for which it holds licenses granted by other laboratories for specific periods, in accordance with the terms and conditions contained in the agreements entered into with said laboratories.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.